From January 16–18, 2026, the CSCO Leukemia, Lymphoma, and Myeloma Expert Committee Working Meeting and the 2026 CSCO Hematologic Oncology Conference were held in Haikou. Guided by the overarching vision of “Greater Hematology, Greater Public Health, and Greater Health,” CSCO’s hematology committees have built a four-pillar framework centered on standardization, clinical support, collaboration, and prognostic assessment, and a three-core value system emphasizing guideline implementation, resource decentralization, and academic empowerment.To address the longstanding gap between clinical guidelines and real-world practice, promote the downward flow of high-quality medical resources, and strengthen national talent pipelines, the Chair of the CSCO Leukemia Expert Committee, Professor Erlie Jiang from the Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, presented a comprehensive summary of 2025 initiatives and the 2026 strategic roadmap.
2025 Roadshow Overview: Strategic Design and Key Initiatives
In 2025, the CSCO Leukemia Guideline Roadshow strategically delivered 20 planned academic events, successfully completing 17 in-person and 3 online sessions across 16 provinces and regions, spanning coastal, western, northeastern, and border areas. The program engaged over 300,000 healthcare professionals nationwide, forming a year-round academic dissemination network, launched in Tianjin (March 15, 2025) and concluded in Harbin (December 26, 2025).
Three Core Workstreams
- Comprehensive guideline updates in leukemia and transplantation, with structured national dissemination
- Leadership in organizing the 28th CSCO Annual Meeting leukemia track, highlighting clinical breakthroughs
- Focus on three innovation frontiers: Targeted therapy (Menin inhibitors) Immunotherapy (CAR-T optimization) Transplant innovation (donor selection & post-transplant management)
Key Site Highlights and Academic Contributions
Tianjin Launch Event
Released four landmark evidence-based advances:
- Optimization of haploidentical HSCT donor strategies
- Targeted–immuno–epigenetic combination pathways in AML
- Improved outcomes in CAR-T for relapsed/refractory leukemia
- Personalized pediatric leukemia precision protocols
Ningbo Stop
Presented evidence on:
- MPN blast-phase transplant strategies
- Risk-adapted DLBCL management
- Genetic screening for secondary myeloid neoplasms post-CAR-T
- Precision AML targeted combinations Expanded discourse on clonal hematopoiesis, CNS prophylaxis, and AI-driven molecular classification.
Chengdu Stop
Reported four major evidence updates:
- >80% CR rates with CAR-T in R/R ALL
- High-risk transplant mortality reduced to <5% via multimodal early-warning systems
- >70% deep molecular response in Ph+ leukemia with third-generation TKIs
- Standardization of targeted–immuno–transplant sequential AML induction
Harbin Specialty Forum
Delivered eight thematic updates across T-LGLL, AA, AIHA, elderly AML low-intensity regimens, MDS molecular stratification, MRD-driven chemo-free ALL pathways, CML TKI dose optimization, APL/AML/Ph+ALL chemo-free home treatment models, and ALAL precision classification — reinforcing evidence-driven personalized leukemia care.
Shenzhen Stop
Focused on AML/transplant and ALL/CML, interpreting 2025 CSCO Acute Leukemia Guideline updates, transplant indications, MRD-guided interventions, and real-world cases to standardize care in the Greater Bay Area.
Shanghai Stop
Released nine high-impact evidence updates including:
- Low-toxicity transplant conditioning
- FLT3/TP53 AML targeted combinations
- Venetoclax + Azacitidine + G-CSF in elderly AML
- Bispecific antibody advances
- ALL molecular testing & immunotherapy updates
Jinan CSCO Annual Meeting Session
Highlighted seven evidence-based milestones:
- The “Tianjin Model” transplant prediction system
- Chemo-free TKI-immunotherapy for Ph+ ALL
- Genetically stratified AML induction
- Functional cure data for hematologic oncology novel agents
- Precision therapy for secondary AML
- Pediatric CML transplant stratification
- Early intensified intervention for FLT3-ITD/NPM1/DNMT3A triple-mutant AML
Suzhou Stop
Emphasized:
- Low-toxicity transplant conditioning
- CBF-AML real-world cohort evidence
- KMT2A/NUP98 & MPAL molecular classification
- FLT3 & ETP-ALL targeted combinations
- QuANTUM-First trial evidence demonstrating OS benefit with quizartinib + standard chemotherapy
Chongqing Stop
Addressed adult ALL molecular profiling, MRD-guided risk adaptation, ETP-ALL high-risk optimization, AML CAR-T and targeted combinations, post-transplant neurologic complications, and CRE infection control.
ASH 2025 Harbin Update Forum
Presented nine ASH-driven breakthroughs including:
- MSC rescue therapy
- AI-predicted GVHD risk
- Cord blood AML transplant updates
- CAR-NK and BCMA/CD19 bispecific combination strategies
- 2025 CSCO ALL immunotherapy updates
Core Impact: Scale, Depth, and Ecosystem Building
Broad National Reach
- Hybrid format increased remote region participation by 40%
- 45% participation from primary-level hospitals (↑15% YoY)
- Major advancement in equitable academic resource distribution
Clinical Depth and Implementation
- Guideline penetration increased 30%
- 60% of content focused on cutting-edge innovation
- Customized sessions for regional clinical realities
- 12 youth-focused academic programs, expanding national talent pipelines
- Regional faculty speaker proportion increased to 35%
Ecosystem Integration
- Engagement with top pharmaceutical companies, improving innovative drug access by 18%
- Collaboration with 150+ hematology specialty alliances
- Improved national treatment standardization (+25%)
- Increased transplant access (+25%)
- Reduced relapse rates (−8%)
The CSCO Leukemia Roadshow has become a national benchmark academic brand, recognized by 300,000+ clinicians.
2026 Strategic Roadmap
The CSCO Leukemia Expert Committee will focus on four strategic priorities:
1. Guideline Optimization & Regional Expansion
- Integrate latest ASH evidence
- Add 10+ county-level outreach programs
- Achieve nationwide coverage across 30+ cities
2. Innovation Leadership
- Expand cell therapy, targeted therapy, and AI-assisted diagnostics
- Lead multicenter clinical trials
- Promote insurance inclusion for innovative therapies
3. Youth Talent Development
- Expand Leukemia Young Investigators Program
- Launch research incubators & case competitions
- Establish dedicated youth academic tracks
4. Grassroots Empowerment & Digital Support
- Build regional quality-control centers
- Upgrade hybrid education models
- Strengthen remote clinical support networks
A total of 65 national academic outreach programs are planned for 2026.
Ongoing Multicenter Clinical Research
A Phase II multicenter randomized controlled trial is currently underway in high-risk MDS, comparing immediate allo-HSCT vs. bridging therapy followed by transplant, with 54 patients enrolled to date. The study aims to generate high-level evidence to guide clinical decision-making.
Conclusion
The 2025 CSCO Leukemia Guideline Roadshow achieved landmark success by integrating guideline implementation, resource decentralization, academic empowerment, and talent cultivation.
The initiative has evolved beyond academic dissemination — becoming a talent incubator, innovation bridge, and national clinical standard-setting engine, driving leukemia care toward standardization, precision, and nationwide equity.
In 2026, under the guiding principles of “Greater Hematology, Greater Health, and Greater Public Welfare,” CSCO will continue to expand reach, deepen innovation, empower youth, and improve patient outcomes, striving to ensure that every leukemia patient in China can access standardized, evidence-based care.
Expert Profile
Professor Erlie Jiang
Vice President, Institute of Hematology & Blood Diseases Hospital, CAMS Director, Stem Cell Transplantation Center
MD, Chief Physician, PhD/Postdoctoral Supervisor
- Chair, CSCO Leukemia Expert Committee
- Chair, China Primary Healthcare Foundation HSCT Committee
- Leader, China Hematologic Oncology Autologous Transplant Consortium
- Deputy Chair, Chinese Society of Hematology HSCT Group
- Standing Member, China Anti-Cancer Association Hematologic Oncology Committee
- Editorial Board Member, Chinese Journal of Hematology, Leukemia & Lymphoma
